This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Imprimis Pharmaceuticals, Inc. Announces Its Attendance At The American Academy Of Ophthalmology In New Orleans, Nov. 16-19

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117 th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, November 16-19 (Booth #5058). Imprimis' presence at this conference is primarily to continue the pre-launch assessments of two of its proprietary ophthalmic sterile injectable compounded formulations, which Imprimis expects to make available to the ophthalmology community in 2014.

Imprimis will also be hosting two events, during which they will be soliciting feedback from the ophthalmology community regarding the utility and commercialization potential of its proprietary ophthalmic compounded formulations.

To schedule meetings with Imprimis or to attend an Imprimis sponsored event, please contact Forest Flodin, Director of Corporate Development, at fflodin@imprimispharma.com.

ABOUT IMPRIMIS PHARMACEUTICALS:

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company focused on the commercial development of novel drug formulations and proprietary drug delivery vehicles.  Imprimis believes in the power of the clinical interaction of one patient, one physician and one pharmacist to build novel therapeutic approaches that have broad market appeal.  Drug formulations created by pharmacists and physicians for a specific patient's use are investigated using through a proprietary and rigorous evaluation process, the Asset Review Methodology (ARM™), in order to assess potential for commercialization. Following this evaluation process, including clinical development, the company may choose to pursue FDA approval through the FDA's Section 505(b)(2) development pathway, or selectively make its treatment options available to the market through pharmacy compounding.  In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across North America.  The company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.

SAFE HARBOR

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs